Windtree Therapeutics Inc. (NASDAQ: WINT)
$3.94
+0.1200 ( +3.14% ) 2.6K
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Market Data
Open
$3.94
Previous close
$3.82
Volume
2.6K
Market cap
$2.19M
Day range
$3.70 - $3.98
52 week range
$2.89 - $30.06
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
nt | Quarterly Reports | 1 | Apr 02, 2024 |
def | Proxies and info statements | 8 | Mar 12, 2024 |
8-k | 8K-related | 15 | Feb 16, 2024 |
pre | Proxies and info statements | 6 | Feb 12, 2024 |
8-k | 8K-related | 16 | Jan 31, 2024 |
8-k | 8K-related | 15 | Jan 25, 2024 |
8-k | 8K-related | 13 | Jan 22, 2024 |
8-k | 8K-related | 13 | Jan 17, 2024 |
10-q | Quarterly Reports | 54 | Nov 09, 2023 |
8-k | 8K-related | 50 | Nov 09, 2023 |